Results 51 to 60 of about 9,288,830 (350)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved]

open access: yesF1000Research, 2022
Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event.
Yohana Azhar   +3 more
doaj   +1 more source

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

open access: yesJournal of Clinical Oncology, 2017
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).
G. Sledge   +17 more
semanticscholar   +1 more source

Underlying mechanisms of glucocorticoid-induced β-cell death and dysfunction: a new role for glycogen synthase kinase 3

open access: yesCell Death and Disease, 2021
Glucocorticoids (GCs) are widely prescribed for their anti-inflammatory and immunosuppressive properties as a treatment for a variety of diseases. The use of GCs is associated with important side effects, including diabetogenic effects.
Etienne Delangre   +8 more
doaj   +1 more source

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

open access: yesFrontiers in Endocrinology, 2023
Endocrine therapy is the prominent strategy for the treatment of hormone-positive breast cancers. The emergence of resistance to endocrine therapy is a major health concern among hormone-positive breast cancer patients.
Jie Yuan   +11 more
doaj   +1 more source

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

open access: yesClinical Cancer Research, 2021
Purpose: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2 ...
X. Hua   +21 more
semanticscholar   +1 more source

TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2021
Significance Resistance to endocrine therapy is a major obstacle to managing breast cancer. Here, we introduce that tripartite motif protein TRIM47 enhances endocrine therapy resistance and facilitates breast cancer tumorigenesis.
Kotaro Azuma   +5 more
semanticscholar   +1 more source

Endocrine therapy regimen intensity according to EPclin.

open access: yes, 2020
Endocrine therapy regimen intensity according to EPclin.
Veronica Bautista-Piña (177269)   +11 more
core   +1 more source

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer

open access: yes, 2020
Endocrine therapy is the gold-standard treatment for ER-positive/HER2-negative breast cancer. Although its clear benefit, patient compliance is poor (50–80%) due to its long administration period and adverse effects.
Li Yan   +6 more
core   +1 more source

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

open access: yesNew England Journal of Medicine, 2019
BACKGROUND An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in
S. Im   +18 more
semanticscholar   +1 more source

Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

open access: yesObesity Reviews, 2021
The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide.
I. Barone   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy